The HARMONY Alliance is a European Network of Excellence for Big Data in Hematology, consisting of 51 partners. Our goal is unlocking valuable knowledge on hematologic malignancies (HMs).
Blood cancers, or hematologic cancers (e.g. leukemia, lymphoma, and myeloma), affect the production and function of blood cells and account for about 40% of cancer cases in children and about one third of cancer deaths As many blood cancers are rare, and healthcare practice varies across EU, a lack of data on relevant outcomes represents a challenge for clinicians, researchers, and other decision-makers like regulators and HTA bodies, resulting in limitations for patient access to the best healthcare. The HARMONY Alliance aims to use "Big Data and Big Data analytics" to deliver information that will help to improve the care of patients with these diseases.
Next to the HARMONY meetings in Europe and in other continents we extensively use online communication channels to reach to you. Please join our challenge!
The HARMONY Alliance is funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. HARMONY has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Program and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.